Review: Nanostructured Lipid Carriers Sebagai Sistem Penghantaran Obat Rute Oral

Astriani Abdullah, Iyan Sopyan

Abstrak

Nanostructured Lipid Carriers (NLCs) adalah sistem penghantaran obat yang telah banyak digunakan dalam pengembangan formulasi obat oral. NLCs memanfaatkan matriks lipid padat dan cair yang meningkatkan kelarutan dan bioavailabilitas obat, serta memungkinkan pelepasan obat secara terkendali. Artikel ini bertujuan untuk meninjau efektivitas NLCs dalam meningkatkan penyerapan obat BCS kelas II, III, dan IV melalui rute oral. Metode yang digunakan adalah peninjauan literatur dengan menganalisis berbagai studi yang mengevaluasi penggunaan NLCs dalam formulasi obat rute oral. Hasil studi literatur menunjukkan  bahwa NLCs memiliki stabilitas yang tinggi di lingkungan asam lambung sehingga meningkatkan ketahanan obat terhadap degradasi dan mengoptimalkan penghantaran obat ke usus. Selain itu, NLCs mampu menargetkan lokasi tertentu dalam saluran pencernaan, meningkatkan efisiensi terapi, serta mengurangi risiko efek samping sistemik. Oleh karena itu, NLCs memiliki potensi besar untuk meningkatkan efektivitas terapeutik dan optimasi dosis obat dalam formulasi obat oral pada kelas II, III, dan IV.

Kata Kunci

Nanostructured lipid carriers, rute oral, sistem penghantaran obat

Teks Lengkap:

PDF

Referensi

A. Ren et al., “Oral administration microrobots for drug delivery,” Bioact. Mater., vol. 39, no. January, pp. 163–190, 2024, doi: 10.1016/j.bioactmat.2024.05.005.

M. S. Alqahtani, M. Kazi, M. A. Alsenaidy, and M. Z. Ahmad, “Advances in Oral Drug Delivery,” Frontiers in Pharmacology, vol. 12. Frontiers Media S.A., Feb. 19, 2021. doi: 10.3389/fphar.2021.618411.

S. Hua, “Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors,” Front. Pharmacol., vol. 11, no. April, pp. 1–22, 2020, doi: 10.3389/fphar.2020.00524.

C. B. Fox, J. Kim, L. V Le, C. L. Nemeth, H. D. Chirra, and T. A. Desai, “Micro/nanofabricated platforms for oral drug delivery,” J. Control. Release, vol. 219, pp. 431–444, 2015, doi: https://doi.org/10.1016/j.jconrel.2015.07.033.

J. Lou et al., “Advances in Oral Drug Delivery Systems: Challenges and Opportunities,” Pharmaceutics, vol. 15, no. 2, 2023, doi: 10.3390/pharmaceutics15020484.

V. C. Ibekwe, H. M. Fadda, E. L. McConnell, M. K. Khela, D. F. Evans, and A. W. Basit, “Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems,” Pharm. Res., vol. 25, no. 8, pp. 1828–1835, 2008, doi: 10.1007/s11095-008-9580-9.

V. Franco, P. Gershkovich, E. Perucca, and M. Bialer, “The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations.,” Clin. Pharmacokinet., vol. 59, no. 12, pp. 1493–1500, Dec. 2020, doi: 10.1007/s40262-020-00931-w.

M. Azman, A. H. Sabri, Q. K. Anjani, M. F. Mustaffa, and K. A. Hamid, “Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery,” Pharmaceuticals, vol. 15, no. 8, pp. 1–24, 2022, doi: 10.3390/ph15080975.

A. Borges, V. de Freitas, N. Mateus, I. Fernandes, and J. Oliveira, “Solid lipid nanoparticles as carriers of natural phenolic compounds,” Antioxidants, vol. 9, no. 10, pp. 1–24, 2020, doi: 10.3390/antiox9100998.

A. N. F. Marzaman et al., “Recent Advances in Pharmaceutical Approaches of Antimicrobial Agents for Selective Delivery in Various Administration Routes,” Antibiotics, vol. 12, no. 5, 2023, doi: 10.3390/antibiotics12050822.

V. H. Nguyen, V. N. Thuy, T. V. Van, A. H. Dao, and B. J. Lee, “Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration,” OpenNano, vol. 8, no. August, p. 100064, 2022, doi: 10.1016/j.onano.2022.100064.

X. Wang et al., “Smart drug delivery systems for precise cancer therapy.,” Acta Pharm. Sin. B, vol. 12, no. 11, pp. 4098–4121, Nov. 2022, doi: 10.1016/j.apsb.2022.08.013.

S. Hua, E. Marks, J. J. Schneider, and S. Keely, “Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue,” Nanomedicine Nanotechnology, Biol. Med., vol. 11, no. 5, pp. 1117–1132, 2015, doi: 10.1016/j.nano.2015.02.018.

B. Gaba, M. Fazil, A. Ali, S. Baboota, J. K. Sahni, and J. Ali, “Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration,” Drug Deliv., vol. 22, no. 6, pp. 691–700, 2015, doi: 10.3109/10717544.2014.898110.

M. Liu, F. Wang, C. Pu, W. Tang, and Q. Sun, “Nanoencapsulation of lutein within lipid-based delivery systems: Characterization and comparison of zein peptide stabilized nano-emulsion, solid lipid nanoparticle, and nano-structured lipid carrier.,” Food Chem., vol. 358, p. 129840, Oct. 2021, doi: 10.1016/j.foodchem.2021.129840.

N. Izza et al., “Systematic Characterization of Nanostructured Lipid Carriers from Cetyl Palmitate/Caprylic Triglyceride/Tween 80 Mixtures in an Aqueous Environment,” Langmuir, vol. 37, no. 14, pp. 4284–4293, 2021, doi: 10.1021/acs.langmuir.1c00270.

N. Dhiman, R. Awasthi, B. Sharma, H. Kharkwal, and G. T. Kulkarni, “Lipid Nanoparticles as Carriers for Bioactive Delivery,” Front. Chem., vol. 9, no. April, 2021, doi: 10.3389/fchem.2021.580118.

N. Poonia, R. Kharb, V. Lather, and D. Pandita, “Nanostructured lipid carriers: Versatile oral delivery vehicle,” Futur. Sci. OA, vol. 2, no. 3, 2016, doi: 10.4155/fsoa-2016-0030.

C. M. O’Driscoll and B. T. Griffin, “Biopharmaceutical challenges associated with drugs with low aqueous solubility-The potential impact of lipid-based formulations,” Adv. Drug Deliv. Rev., vol. 60, no. 6, pp. 617–624, 2008, doi: 10.1016/j.addr.2007.10.012.

A. Mishra et al., “Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation.,” Drug Deliv., vol. 23, no. 4, pp. 1486–1494, May 2016, doi: 10.3109/10717544.2016.1165314.

S. Carregal-Romero et al., “MRI study of the influence of surface coating aging on the in vivo biodistribution of iron oxide nanoparticles,” Biosensors, vol. 8, no. 4, pp. 1–12, 2018, doi: 10.3390/bios8040127.

R. K. Shirodkar, L. Kumar, S. Mutalik, and S. Lewis, “Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Emerging Lipid Based Drug Delivery Systems,” Pharm. Chem. J., vol. 53, no. 5, pp. 440–453, 2019, doi: 10.1007/s11094-019-02017-9.

P. Jaiswal, B. Gidwani, and A. Vyas, “Nanostructured lipid carriers and their current application in targeted drug delivery,” Artif. Cells, Nanomedicine Biotechnol., vol. 44, no. 1, pp. 27–40, 2016, doi: 10.3109/21691401.2014.909822.

F. Brugè, E. Damiani, F. Marcheggiani, A. Offerta, C. Puglia, and L. Tiano, “A comparative study on the possible cytotoxic effects of different nanostructured lipid carrier (NLC) compositions in human dermal fibroblasts,” Int. J. Pharm., vol. 495, no. 2, pp. 879–885, 2015, doi: 10.1016/j.ijpharm.2015.09.033.

S. Doktorovova, E. B. Souto, and A. M. Silva, “Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers - A systematic review of in vitro data,” Eur. J. Pharm. Biopharm., vol. 87, no. 1, pp. 1–18, 2014, doi: 10.1016/j.ejpb.2014.02.005.

A. B. Buya, A. Beloqui, P. B. Memvanga, and V. Préat, “Self-Nano-Emulsifying Drug-Delivery Systems: From the Development to the Current Applications and Challenges in Oral Drug Delivery.,” Pharmaceutics, vol. 12, no. 12, Dec. 2020, doi: 10.3390/pharmaceutics12121194.

Y. Liu et al., “Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin,” Int. J. Pharm., vol. 476, no. 1, pp. 169–177, 2014, doi: 10.1016/j.ijpharm.2014.09.052.

N. Dudhipala, K. Y. Janga, and T. Gorre, “Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation,” Artif. Cells, Nanomedicine Biotechnol., vol. 46, no. sup2, pp. 616–625, 2018, doi: 10.1080/21691401.2018.1465068.

J. Luan, F. Zheng, X. Yang, A. Yu, and G. Zhai, “Nanostructured lipid carriers for oral delivery of baicalin: In vitro and in vivo evaluation,” Colloids Surfaces A Physicochem. Eng. Asp., vol. 466, pp. 154–159, 2015, doi: 10.1016/j.colsurfa.2014.11.015.

L. Mandpe and V. Pokharkar, “Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement,” Pharm. Dev. Technol., vol. 20, no. 3, pp. 320–329, 2015, doi: 10.3109/10837450.2013.867445.

C. Lin et al., “A novel oral delivery system consisting in ‘drug-in cyclodextrin-in nanostructured lipid carriers’ for poorly water-soluble drug: Vinpocetine,” Int. J. Pharm., vol. 465, no. 1–2, pp. 90–96, 2014, doi: 10.1016/j.ijpharm.2014.02.013.

K. M. Hosny, R. H. Bahmdan, N. A. Alhakamy, M. A. Alfaleh, O. A. Ahmed, and M. H. Elkomy, “Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis,” J. Pharm. Sci., pp. 1–11, 2020, doi: 10.1016/j.xphs.2020.03.009.

A. A. Khan, J. Mudassir, S. Akhtar, V. Murugaiyah, and Y. Darwis, “Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: Statistical optimization, in vitro and in vivo evaluations,” Pharmaceutics, vol. 11, no. 2, pp. 1–19, 2019, doi: 10.3390/pharmaceutics11020097.

M. Elmowafy, H. M. Ibrahim, M. A. Ahmed, K. Shalaby, A. Salama, and H. Hefesha, “Atorvastatin-loaded nanostructured lipid carriers (Nlcs): Strategy to overcome oral delivery drawbacks,” Drug Deliv., vol. 24, no. 1, pp. 932–941, 2017, doi: 10.1080/10717544.2017.1337823.

M. Cirri et al., “Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy,” Drug Deliv., vol. 25, no. 1, pp. 1910–1921, 2018, doi: 10.1080/10717544.2018.1529209.

F. L. Lüdtke, R. Grimaldi, L. P. Cardoso, M. L. Gigante, A. A. Vicente, and A. P. B. Ribeiro, “Development and Characterization of Fully Hydrogenated Soybean Oil and High Oleic Sunflower Oil β-carotene Loaded Nanostructured Lipid Carriers,” Food Biophys., vol. 18Lüdtke, no. 3, pp. 338–352, 2023, doi: 10.1007/s11483-023-09777-8.

S. Faiz et al., “Pioglitazone-loaded nanostructured lipid carriers: In-vitro and in-vivo evaluation for improved bioavailability,” J. Drug Deliv. Sci. Technol., vol. 79, no. November 2022, p. 104041, 2023, doi: 10.1016/j.jddst.2022.104041.

H. Rouco et al., “Rifabutin-loaded nanostructured lipid carriers as a tool in oral anti-mycobacterial treatment of crohn’s disease,” Nanomaterials, vol. 10, no. 11, pp. 1–18, 2020, doi: 10.3390/nano10112138.

A. Zafar, M. Yasir, D. S. Panda, and L. Singh, “Bergenin nano-lipid carrier to improve the oral delivery: Development, optimization, in vitro and in vivo evaluation,” J. Drug Deliv. Sci. Technol., vol. 96, no. January, p. 105655, 2024, doi: 10.1016/j.jddst.2024.105655.

A. Sartaj et al., “Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating In Vitro Specification, and In Vivo Scrutinization,” Biomed Res. Int., vol. 2022, 2022, doi: 10.1155/2022/6009309.

H. O. Ammar, M. M. Ghorab, M. S. Saleh, and A. M. Ghoneim, “Olanzapine Mesoporous Nanostructured Lipid Carrier: Optimization, Characterization, in Vivo Assessment, and Physiologically Based Pharmacokinetic Modeling,” IEEE Trans. Nanobioscience, vol. 20, no. 2, pp. 166–174, 2021, doi: 10.1109/TNB.2021.3052080.

T. Alam, M. A. Ansari, S. Baboota, and J. Ali, “Nanostructured lipid carriers of isradipine for effective management of hypertension and isoproterenol induced myocardial infarction,” Drug Deliv. Transl. Res., vol. 12, no. 3, pp. 577–588, 2022, doi: 10.1007/s13346-021-00958-x.

A. Motawea, W. E. Abd El Hady, and G. Ahmed El-Emam, “The protective impact of adapted trimebutine maleate-loaded nanostructured lipid carriers for alleviating the severity of acute colitis,” Drug Deliv., vol. 29, no. 1, pp. 906–924, 2022, doi: 10.1080/10717544.2022.2050847.

S. Bhatt, J. B. Sharma, R. Kamboj, M. Kumar, V. Saini, and S. Mandge, “Design and optimization of febuxostat-loaded nano lipid carriers using full factorial design,” Turkish J. Pharm. Sci., vol. 18, no. 1, pp. 61–67, 2021, doi: 10.4274/tjps.galenos.2019.32656.

A. Zafar, “Development of oral lipid based nano-formulation of dapagliflozin: Optimization, in vitro characterization and ex vivo intestinal permeation study,” J. Oleo Sci., vol. 69, no. 11, pp. 1389–1401, 2020, doi: 10.5650/jos.ess20162.

N. Bertrand and J.-C. Leroux, “The journey of a drug-carrier in the body: an anatomo-physiological perspective,” J. Control. release, vol. 161, no. 2, pp. 152–163, 2012.

S. Tan, T. Wu, D. Zhang, and Z. Zhang, “Cell or cell membrane-based drug delivery systems,” Theranostics, vol. 5, no. 8, p. 863, 2015.

W. Shinoda, “Permeability across lipid membranes,” Biochim. Biophys. Acta - Biomembr., vol. 1858, no. 10, pp. 2254–2265, 2016, doi: 10.1016/j.bbamem.2016.03.032.

M. Sharifian Gh, “Recent experimental developments in studying passive membrane transport of drug molecules,” Mol. Pharm., vol. 18, no. 6, pp. 2122–2141, 2021.

D. Dahlgren and H. Lennernäs, “Intestinal permeability and drug absorption: predictive experimental, computational and in vivo approaches,” Pharmaceutics, vol. 11, no. 8, 2019, doi: 10.3390/pharmaceutics11080411.

D. M. Oh, R. L. Curl, and G. L. Amidon, “Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model.,” Pharm. Res., vol. 10, no. 2, pp. 264–270, Feb. 1993, doi: 10.1023/a:1018947113238.

Y. Tsume, D. M. Mudie, P. Langguth, G. E. Amidon, and G. L. Amidon, “The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.,” Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci., vol. 57, pp. 152–163, Jun. 2014, doi: 10.1016/j.ejps.2014.01.009.

S. Y. K. Fong, A. Ibisogly, and A. Bauer-Brandl, “Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying,” Int. J. Pharm., vol. 496, no. 2, pp. 382–391, 2015, doi: https://doi.org/10.1016/j.ijpharm.2015.10.029.

A. Parr et al., “The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers.,” Pharm. Res., vol. 33, no. 1, pp. 167–176, Jan. 2016, doi: 10.1007/s11095-015-1773-4.

V. Asati Amit, S. Salunkhe Kishor, J. Chavan Machindra, B. Chintamani Ravindra, and R. S. R. Pratap, “Solubility enhancement of BCS classified IV drug-apixaban by preparation and evaluation of mesoporous nanomatrix,” Int. J. Res. Pharm. Sci., vol. 11, no. 1, pp. 880–890, 2020, doi: 10.26452/ijrps.v11i1.1910.

B. Krishnamoorthy et al., “Design, formulation, in vitro, in vivo, and pharmacokinetic evaluation of nisoldipine-loaded self-nanoemulsifying drug delivery system,” J. Nanoparticle Res., vol. 17, pp. 1–11, 2015.

H. Wu et al., “Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound, baicalin.,” Acta Pharm. Sin. B, vol. 4, no. 3, pp. 217–226, Jun. 2014, doi: 10.1016/j.apsb.2014.03.002.

R. Bhadale and V. Londhe, “Inclusion Complex of Iloperidone with Sulfobutyl Ether Beta-Cyclodextrin: Characterization and Dissolution Studies,” p. 22, 2021, doi: 10.3390/iecp2020-08715.

P. Sun et al., “Controlled recrystallization of tubular vinpocetine crystals with increased aqueous dissolution rate and in vivo bioavailability,” Cryst. Growth Des., vol. 17, no. 11, pp. 5790–5800, 2017.

A. Jain, R. Kaur, S. Beg, V. Kushwah, S. Jain, and B. Singh, “Novel cationic supersaturable nanomicellar systems of raloxifene hydrochloride with enhanced biopharmaceutical attributes.,” Drug Deliv. Transl. Res., vol. 8, no. 3, pp. 670–692, Jun. 2018, doi: 10.1007/s13346-018-0514-8.

M. C. Braithwaite, Y. E. Choonara, P. Kumar, L. K. Tomar, L. C. Du Toit, and V. Pillay, “A novel bile salts–lipase polymeric film-infused minitablet system for enhanced oral delivery of cholecalciferol,” Pharm. Dev. Technol., vol. 21, no. 7, pp. 832–846, 2016.

A. M. Saeed et al., “Comparative bioavailability of two formulations of biopharmaceutical classification system (BCS) class IV drugs: A case study of lopinavir/ritonavir,” J. Pharm. Sci., vol. 110, no. 12, pp. 3963–3968, 2021.

O. Okorie, C. P. Azubuike, M. Ilomuanya, and U. Ubani-Ukoma, “Comparative in vitro and in vivo Bioequivalence Analysis of some Brands of film coated Atorvastatin (a BCS Class II Compound) tablets marketed in Nigeria,” J. Reports Pharm. Sci., vol. 5, no. 2, pp. 112–121, 2016.

M. Ruponen, H. Rusanen, and R. Laitinen, “Dissolution and permeability properties of co-amorphous formulations of hydrochlorothiazide,” J. Pharm. Sci., vol. 109, no. 7, pp. 2252–2261, 2020.

A. Kulkarni, T. Madane, N. Aloorkar, and S. Mujumdar, “Enhancement of solubility of BCS class II drug (pioglitazone) using natural polymer (pullulan),” J. Curr. Pharma Res., vol. 9, no. 4, pp. 3321–3334, 2019.

M. Elmowafy et al., “Influence of stabilizer on the development of luteolin nanosuspension for cutaneous delivery: An in vitro and in vivo evaluation,” Pharmaceutics, vol. 13, no. 11, 2021, doi: 10.3390/pharmaceutics13111812.

W. Zauner, N. A. Farrow, and A. M. R. Haines, “In vitro uptake of polystyrene microspheres : effect of particle size , cell line and cell density,” vol. 71, pp. 39–51, 2001.

J. Pardeike, A. Hommoss, and R. H. Müller, “Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products,” Int. J. Pharm., vol. 366, no. 1–2, pp. 170–184, 2009, doi: 10.1016/j.ijpharm.2008.10.003.

R. Kashapov et al., “Nanocarriers for Biomedicine: From Lipid Formulations to Inorganic and Hybrid Nanoparticles.,” Int. J. Mol. Sci., vol. 22, no. 13, Jun. 2021, doi: 10.3390/ijms22137055.

N. M. Noor, K. Sheikh, S. Somavarapu, and K. M. G. Taylor, “Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery,” Eur. J. Pharm. Biopharm., vol. 117, pp. 372–384, 2017, doi: 10.1016/j.ejpb.2017.04.012.

M. Elmowafy and M. M. Al-Sanea, “Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies,” Saudi Pharm. J., vol. 29, no. 9, pp. 999–1012, 2021, doi: 10.1016/j.jsps.2021.07.015.

A. Khosa, S. Reddi, and R. N. Saha, “Nanostructured lipid carriers for site-specific drug delivery,” Biomed. Pharmacother., vol. 103, no. February, pp. 598–613, 2018, doi: 10.1016/j.biopha.2018.04.055.

T. Miyazawa, M. Itaya, G. C. Burdeos, K. Nakagawa, and T. Miyazawa, “A Critical Review of the Use of Surfactant-Coated Nanoparticles in Nanomedicine and Food Nanotechnology.,” Int. J. Nanomedicine, vol. 16, pp. 3937–3999, 2021, doi: 10.2147/IJN.S298606.

A. Pezeshki, “Effect of Surfactant Concentration on the Particle Size , Stability and Potential Zeta of Beta carotene Nano Lipid Carrier Original Research Article Effect of Surfactant Concentration on the Particle Size , Stability and Potentia,” Int. J. Curr. Microbiol. Appl. Sci., vol. 4, no. September, pp. 924–932, 2017.

K. Zheng et al., “The effect of polymer–surfactant emulsifying agent on the formation and stability of α-lipoic acid loaded nanostructured lipid carriers (NLC),” Food Hydrocoll., vol. 32, no. 1, pp. 72–78, 2013, doi: https://doi.org/10.1016/j.foodhyd.2012.11.006.

K. W. Wu et al., “Primaquine Loaded Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), and Nanoemulsion (NE): Effect of Lipid Matrix and Surfactant on Drug Entrapment, in vitro Release, and ex vivo Hemolysis,” AAPS PharmSciTech, vol. 22, no. 7, 2021, doi: 10.1208/s12249-021-02108-5.

A. Chaudhuri et al., “Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy.,” Int. J. Mol. Sci., vol. 23, no. 17, Sep. 2022, doi: 10.3390/ijms231710068.

I. Chauhan, M. Yasir, M. Verma, and A. P. Singh, “Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery,” Adv. Pharm. Bull., vol. 10, no. 2, pp. 150–165, 2020, doi: 10.34172/apb.2020.021.

K. Bhise, S. K. Kashaw, S. Sau, and A. K. Iyer, “Nanostructured lipid carriers employing polyphenols as promising anticancer agents: Quality by design (QbD) approach.,” Int. J. Pharm., vol. 526, no. 1–2, pp. 506–515, Jun. 2017, doi: 10.1016/j.ijpharm.2017.04.078.

V. A. Duong, T. T. L. Nguyen, and H. J. Maeng, “Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method,” Molecules, vol. 25, no. 20, pp. 1–36, 2020, doi: 10.3390/molecules25204781.

R. John, J. Monpara, S. Swaminathan, and R. Kalhapure, “Chemistry and Art of Developing Lipid Nanoparticles for Biologics Delivery: Focus on Development and Scale-Up.,” Pharmaceutics, vol. 16, no. 1, Jan. 2024, doi: 10.3390/pharmaceutics16010131.

V. Jannin, L. Blas, S. Chevrier, C. Miolane, F. Demarne, and D. Spitzer, “Evaluation of the digestibility of solid lipid nanoparticles of glyceryl dibehenate produced by two techniques: Ultrasonication and spray-flash evaporation,” Eur. J. Pharm. Sci., vol. 111, no. September 2017, pp. 91–95, 2018, doi: 10.1016/j.ejps.2017.09.049.

J. Zhu, Y. Huang, J. Zhang, Y. Feng, and L. Shen, “Formulation, preparation and evaluation of nanostructured lipid carrier containing naringin and coix seed oil for anti-tumor application based on ‘unification of medicines and excipients,’” Drug Des. Devel. Ther., vol. 14, pp. 1481–1491, 2020, doi: 10.2147/DDDT.S236997.

V. Andonova and P. Peneva, “Characterization Methods for Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC),” Curr. Pharm. Des., vol. 23, no. 43, pp. 6630–6642, 2018, doi: 10.2174/1381612823666171115105721.

E. Lasoń, E. Sikora, and J. Ogonowski, “Influence of process parameters on properties of nanostructured lipid carriers (NLC) formulation,” Acta Biochim. Pol., vol. 60, no. 4, pp. 773–777, 2013, doi: 10.18388/abp.2013_2056.

L. Chen and R. Wu, “Brinzolamide- and latanoprost-loaded nano lipid carrier prevents synergistic retinal damage in glaucoma.,” Acta Biochim. Pol., vol. 69, no. 2, pp. 423–428, May 2022, doi: 10.18388/abp.2020_5885.

Z. Németh et al., “Quality by Design-Driven Zeta Potential Optimisation Study of Liposomes with Charge Imparting Membrane Additives,” Pharmaceutics, vol. 14, no. 9, 2022, doi: 10.3390/pharmaceutics14091798.

A. B. Kovačević, R. H. Müller, S. D. Savić, G. M. Vuleta, and C. M. Keck, “Solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants: Preparation, characterization and physical stability investigation,” Colloids Surfaces A Physicochem. Eng. Asp., vol. 444, pp. 15–25, 2014, doi: 10.1016/j.colsurfa.2013.12.023.

M. Danaei et al., “Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems,” Pharmaceutics, vol. 10, no. 2, pp. 1–17, 2018, doi: 10.3390/pharmaceutics10020057.

R. Hasham and U. Teknologi, “Effects of Formulation Parameters on Particle Size and Polydispersity Index of Orthosiphon Stamineus Loaded Nanostructured ... Akademia Baru Effects of Formulation Parameters on Particle Size and Polydispersity Index of Orthosiphon Stamineus Loaded Nanost,” vol. 1, no. November 2015, pp. 36–39, 2016.

S. S. Rane and P. Choi, “Polydispersity Index: How Accurately Does It Measure the Breadth of the Molecular Weight Distribution?,” Chem. Mater., vol. 17, no. 4, p. 926, Feb. 2005, doi: 10.1021/cm048594i.

H. Wu et al., “Determination of Ferulic Acid in Angelica sinensis by Temperature-Controlled Hydrophobic Ionic Liquids-Based Ultrasound/Heating-Assisted Extraction Coupled with High Performance Liquid Chromatography.,” Molecules, vol. 25, no. 15, Jul. 2020, doi: 10.3390/molecules25153356.

S. Daneshmand et al., “Encapsulation challenges, the substantial issue in solid lipid nanoparticles characterization,” J. Cell. Biochem., vol. 119, no. 6, pp. 4251–4264, 2018, doi: 10.1002/jcb.26617.

A. M. Al-Mahallawi, A. A. Abdelbary, and S. A. El-Zahaby, “Norfloxacin loaded nano-cubosomes for enhanced management of otitis externa: In vitro and in vivo evaluation.,” Int. J. Pharm., vol. 600, p. 120490, May 2021, doi: 10.1016/j.ijpharm.2021.120490.

P. A. Midgley and M. Weyland, “3D electron microscopy in the physical sciences: the development of Z-contrast and EFTEM tomography,” Ultramicroscopy, vol. 96, no. 3, pp. 413–431, 2003, doi: https://doi.org/10.1016/S0304-3991(03)00105-0.

S. Singh, A. K. Kushwaha, P. R. Vuddanda, P. Karunanidhi, and S. K. Singh, “Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability,” Biomed Res. Int., vol. 2013, 2013, doi: 10.1155/2013/584549.

H. S. Rahman et al., “Acute Toxicity Study of Zerumbone-Loaded Nanostructured Lipid Carrier on BALB/c Mice Model,” Biomed Res. Int., vol. 2014, 2014, doi: 10.1155/2014/563930.

G. I. Harisa, A. H. Alomrani, and M. M. Badran, “Simvastatin-loaded nanostructured lipid carriers attenuate the atherogenic risk of erythrocytes in hyperlipidemic rats.,” Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci., vol. 96, pp. 62–71, Jan. 2017, doi: 10.1016/j.ejps.2016.09.004.

S. Khan, S. Baboota, J. Ali, S. Khan, R. S. Narang, and J. K. Narang, “Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs,” Int. J. Pharm. Investig., vol. 5, no. 4, pp. 182–191, 2015, doi: 10.4103/2230-973X.167661.

A. Beloqui, M. A. Solinís, A. Delgado, C. Évora, A. Isla, and A. Rodríguez-Gascón, “Fate of nanostructured lipid carriers (NLCs) following the oral route: Design, pharmacokinetics and biodistribution,” J. Microencapsul., vol. 31, no. 1, pp. 1–8, 2014, doi: 10.3109/02652048.2013.788090.

DOI: https://doi.org/10.24198/mfarmasetika.v9i6.58645

Refbacks

  • Saat ini tidak ada refbacks.


Bookmark and Share